

EVENT PROGRAM

Day 1. November 17 (Thursday)

10.00 – 10.30	Arrival, registration, coffee and sandwich
10.30 – 10.35	Welcome and general information
10.35 – 11.20	SESSION 1: Therapy preclinical Chairs: Anja Mortensen and Vladimir Tolmachev 10.35 – 10.50 Maryam Oroujeni, Uppsala University Evaluation of an Affibody-Based Binder for Targeting of Immune Check-Point Molecule B7-H3 10.50 – 11.05 Tabassom Mohajershojai, Uppsala University Therapeutic effects of ¹⁷⁷ Lu-DOTA-M5A anti-carcinoembryonic antigen humanized antibody are enhanced when combined with HSP90 inhibitor in colorectal cancer 11.05 – 11.20 Yongsheng Liu, Uppsala University Therapy of HER2-expressing human xenografts in mice using ¹⁷⁷ Lu-labelled scaffold protein aby-027: comparison with therapy using antibody trastuzumab
11.20 – 11.30	Break (10 min)
11.30 – 12.15	INVITED SPEAKER (Zoom) Cristina Müller, PD Ph.D. (Paul Scherrer Institute, Switzerland)
12.15 – 13.00	SESSION 2: Therapy preclinical Chairs: Diana Spiegelberg and Bo Stenerlöv 12.15 – 12.30 Maryam Oroujeni, Uppsala University Preclinical Evaluation of HER2-targeting DARPIn G3: Impact of Albumin Binding Domain (ABD) Fusion 12.30 – 12.45 Mikael Elvborn, Gothenburg University Hyper-fractionation of ¹⁷⁷ Lu-octreotate increases the uptake in human GOT1 tumours in a mouse model 12.45 – 13.00 Hanna Berglund, Uppsala University p53-Mediated Radiosensitization of ¹⁷⁷ Lu-DOTATATE in Neuroblastoma Tumor Spheroids
13.00 – 14.00	LUNCH

14.00 – 14.30	SESSION 3: Imaging preclinical Chairs: Maryam Oroujeni and Mohamed Altai 14.00 – 14.15 Diana Spiegelberg, Uppsala University Targeting mutant p53: Evaluation of novel anti- p53R175H monoclonal antibodies as agents for molecular imaging 14.15 – 14.30 Ayman Abouzayed, Uppsala University Preclinical characterization of a stabilized GRPR antagonist for targeted cancer theranostics
14.30 – 14.45	Break
14.45 – 15.30	INVITED SPEAKER Assistant Professor David Ulmert, M.D. Ph.D. (Lund University / University of California Los Angeles)
15.30 – 16.00	Coffee, fika
16.00 – 17.00	Discussion session with the experts in a specific field (3 experts, in parallel)
17.00 – 17.30	Network activity (Tipsrunda)
17.30 – 18.30	Swedish radiobiological society
18.30 – 21.00	DINNER

Day 2. November 18 (Friday)

9.00 – 10.00	SESSION 4: Therapy preclinical Chairs: Maryam Oroujeni and Anna Orlova 9.00 – 9.15 Yongsheng Liu, Uppsala University Treatment of HER2-expressing Human Xenografts Using Affibody Molecule ¹⁸⁸ Re-Z41071 in Mice Model 9.15 – 9.30 Mostafa Karimi Roshan, Stockholm University Neutron Enhanced Capture Treatment of Neurotoxic Amyloid AggRegates project (NECTAR) – a new approach to address Alzheimer’s treatment 9.30 – 9.45 Anders Örbom, Lund University High activity fractionated treatment with ¹⁷⁷ Lu-PSMA-617 in a mouse model to investigate α1-microglobulin as a kidney radioprotector 9.45 – 10.00 Anzhelika Vorobyeva, Uppsala University Evaluation of influence of cytotoxic payload on biodistribution of HER2-targeting affibody-drug conjugates using a radioactive label
10.00 – 10.15	Coffee break (15 min)
10.15 – 11.00	SESSION 5: Theranostics Chairs: Anzhelika Vorobyeva and Eva Forssell-Aronsson 10.15 – 10.30 Cecilia Hindorf, Karolinska Institutet Simplified imaging protocol after ¹⁷⁷ Lu-DOTATATE treatment with sufficient accuracy in kidney- and tumour dosimetry 10.30 – 10.45 Joachim N. Nilsson, Karolinska Institutet Identifying thyroid cancers with low pre-therapeutic iodine avidity – best predictors from multivariate modelling 10.45 – 11.00 Mohamed Altai, Lund University Development of novel Radioimmuno-theranostic compounds targeting Leucine-Rich Repeat-Containing protein 15 (LRRC15), a TGFβ-driven pan-cancer biomarker
11.00 – 11.15	Coffee break (15 min)

11.15 – 12.10	<p>Rapid fire talks (3 min talk + 2 min questions)</p> <p>Chairs: Marika Nestor and Eva Forssell-Aronsson Sara Lundsten, Uppsala University</p> <p>Preclinical characterization of ¹⁷⁷Lu-DOTATATE binding and internalization</p> <p>Emma Jussing, Karolinska Institutet</p> <p>Preparation and cGMP-compliant production of the bombesin analogue [⁶⁸Ga]Ga-NOTA-RM26 for first-in-human clinical study of gastrin-releasing peptide receptor expression in prostate cancer</p> <p>Jonathan Siikanen, Karolinska Institutet</p> <p>Production of ⁵⁵Co using pressed nickel and magnesium foils</p> <p>Daniel Roth, Lund University</p> <p>A 3D-printed mouse phantom for the evaluation of a hand-held CZT-based gamma camera</p> <p>Lukas Lundholm, Gothenburg University</p> <p>VERDICT MRI for estimation of intracellular volume fraction and cell radius: comparison with histology in a mouse model of neuroendocrine tumor</p> <p>Chiara Timperanza, Gothenburg University</p> <p>Development of Astatine-211 Radiopharmaceuticals for Pretargeted Radioimmunotherapy of Disseminated Cancer</p> <p>Carl Fredrik Warfvinge, Lund University</p> <p>Relationship between tumor absorbed doses and tumor response in neuroendocrine tumors treated with ¹⁷⁷Lutetium-DOTATATE</p> <p>Julia Uffenrode, Uppsala University</p> <p>Identification of genetic and epigenetic biomarkers for predicting therapy response in head and neck cancer</p> <p>Curium and SAM Nordic sponsorship talk 10 min</p>
12.10 – 12.30	Award ceremony, summary, closing of the meeting
	Lunch sandwich to go

Time allocation for oral presentations:

- **PARTICIPANTS: 10 min + 5 min questions**
- **INVITED SPEAKERS: 30 min + 15 min questions**
- **Day 1: 9 oral presentations + 2 invited speakers**
- **Day 2: 8 oral presentations + 6 Rapid fire talks**